A study has found that most cancer drugs granted accelerated approval in the US did not show benefits in overall survival or quality of life in confirmatory trials after more than five years of follow-up. Some drugs improved overall survival, some were withdrawn due to inefficacy, and others had ongoing confirmatory studies. Oncology drugs are increasingly approved through expedited pathways in both the UK and the US. Previous research has also found that many oncology drugs approved by the European Medicines Agency showed limited added benefit, especially when approved through expedited pathways. The study highlights the need for careful evaluation of cancer drugs granted accelerated approval.
Source link
Cancer: Fast tracked drugs often do not improve clinical outcomes, say researchers
